Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00164125 · ClinicalTrials.gov registry record · Phase 4
An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients
A Phase 4 study of Constipation, sponsored by Braintree Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT00164125: Completed Phase 4 study of Constipation, sponsored by Braintree Laboratories.
NCT00164125 is a Phase 4 study of Constipation that has completed, run by Braintree Laboratories. The registered enrollment target is 300 participants, above the 200-participant average among 54 other Constipation trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00164125, a Phase 4 study of Constipation, has completed, sponsored by Braintree Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety of extended use of polyethyleneglycol3350 laxative in constipated patients.
Conditions Studied
Interventions
- DRUG polyethyleneglycol3350
Study Locations (20)
Florida
- - Kissimmee
- - Lake Worth
- - Largo
- - Ocoee
- - St. Petersburg
- - St. Petersburg
- - West Palm Beach
Alabama
- - Hoover
- - Mobile
- - Pell City
- - Tallassee
Arizona
- - Glendale
- - Phoenix
- - Scottsdale
- - Tucson
California
- - Anaheim
- - Sacramento
Georgia
- - Atlanta
- - Marietta
District of Columbia
- - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2003-07 |
| Phase | Phase 4 |
What the finished NCT00164125 record still lists
NCT00164125 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 200-participant average among 54 other Constipation trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Constipation appearing as the primary indexed condition, and to 1 intervention - of which polyethyleneglycol3350 is the first listed.
NCT00164125 names 20 study sites across 6 states, led by Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00164125 about?
NCT00164125 is a clinical study titled "An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients". To evaluate the safety of extended use of polyethyleneglycol3350 laxative in constipated patients.
What is the current status of trial NCT00164125?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2003-07.
What conditions does trial NCT00164125 study?
This clinical trial studies the following conditions: Constipation.
What interventions are being tested in trial NCT00164125?
The interventions under investigation include: polyethyleneglycol3350 (DRUG).
Who is sponsoring clinical trial NCT00164125?
This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00164125 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00164125's enrollment target sits among peer trials
300 5th of 54 higher than 48 of 54 other Constipation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Constipation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery
RECRUITING · Phase 4
-
Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen
RECRUITING · Phase 4
-
Preop Laxatives in Robotic Urologic Surgery
RECRUITING · Phase 4
-
Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients
COMPLETED · Phase 4
-
Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications
COMPLETED · Phase 4
-
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia